{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:07:27Z","timestamp":1791313647233,"version":"4.3.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> To describe demographic, clinical and therapeutic findings of a large cohort of patients with JIA-associated uveitis in a nationwide referral pediatric rheumatology and uveitis center in Northern Italy.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Retrospective study of 125 patients with JIA-associated uveitis followed from 2009 to 2019. Demographic and rheumatologic features including JIA ILAR classification, age at onset, and laboratory data were recorded. Ocular findings collected were: anatomic location of uveitis, laterality, type, recurrence rate, visual acuity, ocular complications, and local therapy. Systemic therapy with conventional and biologic immunosuppressants, occurrence of adverse events, and duration of treatments were recorded.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> One hundred and twenty-five patients with JIA-associated uveitis were followed for a meantime of 9.2 (\u00b11.7) years. Oligoarticular JIA was present in 92.8% of patients and anterior uveitis in 96%. The most common ocular complications recorded in our sample were posterior synechiae (37.6%), cataract (20.8%), band keratopathy (19.2%), glaucoma (7.2%), and macular edema (5.6%). Conventional immunosuppressants were used in 75.2% of patients with a mean duration of 9.1 years (\u00b15.4), while biologics were administered in 47.2% of them for a period of 5.4 years. Adverse events (AE) were seen in 23% of patients being treated with Methotrexate, in 10.4% of patients treated with Adalimumab, in 38.5% of patients in therapy with Infliximab, and in 14.3% of patients being treated with Tocilizumab. No AE were reported in patients treated with Golimumab, Certolizumab, Abatacept and Rituximab.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> An aggressive treatment approach for patients with JIA-associated uveitis ensured a low number of ocular complications with a good safety profile.<\/jats:p>","DOI":"10.3389\/fped.2021.682327","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T05:18:46Z","timestamp":1624857526000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Long Term Experience in Patients With JIA-Associated Uveitis in a Large Referral Center"],"prefix":"10.3389","volume":"9","author":[{"given":"Luca","family":"Marelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pontikaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio Virgilio","family":"Gattinara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Nucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Miserocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.berh.2018.10.004","article-title":"Update on the epidemiology, risk factors and disease outcomes of Juvenile idiopathic arthritis. Best Practice & research","volume":"32","author":"Palman","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet (London, England)."},{"key":"B3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acr.23871","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis","volume":"71","author":"Angeles-Han","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/acr.20524","article-title":"Development of a vision-related quality of life instrument for children ages 8-18 years for use in juvenile idiopathic arthritis-associated uveitis","volume":"63","author":"Angeles-Han","year":"2011","journal-title":"Arthritis Care Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-015-0018-8","article-title":"Characteristics of a cohort of children with Juvenile Idiopathic Arthritis and JIA-associated Uveitis","volume":"13","author":"Angeles-Han","year":"2015","journal-title":"Pediatr Rheumatol Online J."},{"key":"B6","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"3","author":"Petty","year":"2004","journal-title":"J Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jaapos.2008.05.012","article-title":"Granulomatous inflammation in juvenile idiopathic arthritis-associated uveitis","volume":"12","author":"Keenan","year":"2008","journal-title":"J AAPOS."},{"key":"B8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis","volume":"39","author":"Miserocchi","year":"2020","journal-title":"Clin Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"108322","DOI":"10.1016\/j.clim.2019.108322","article-title":"Juvenile idiopathic arthritis-associated uveitis","volume":"211","author":"Sen","year":"2020","journal-title":"Clin Immunol (Orlando, Fla.)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3109\/09273948.2013.791701","article-title":"Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors","volume":"21","author":"Heiligenhaus","year":"2013","journal-title":"Ocular Immunol Inflamm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/rheumatology\/kem053","article-title":"Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines","volume":"46","author":"Heiligenhaus","year":"2007","journal-title":"Rheumatology (Oxford, England)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/s0161-6420(01)00773-4","article-title":"Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study","volume":"108","author":"Kotaniemi","year":"2001","journal-title":"Ophthalmology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/s0161-6420(97)30329-7","article-title":"Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis","volume":"104","author":"Dana","year":"1997","journal-title":"Ophthalmology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/eye.1988.118","article-title":"Uveitis in juvenile chronic arthritis: incidence, clinical features and prognosis","volume":"2","author":"Kanski","year":"1988","journal-title":"Eye (London, England)."},{"key":"B16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/09273948.2016.1142573","article-title":"Occurrence of and risk factors for ocular hypertension and secondary glaucoma in juvenile idiopathic arthritis-associated uveitis","volume":"25","author":"Stroh","year":"2017","journal-title":"Ocular Immunol Inflamm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/09273948.2013.871566","article-title":"Development of macular edema and impact on visual acuity in uveitis associated with juvenile idiopathic arthritis","volume":"23","author":"de Boer","year":"2015","journal-title":"Ocular Immunol Inflamm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3109\/09273948.2013.855798","article-title":"Juvenile idiopathic arthritis-associated uveitis at an Italian tertiary referral center: clinical features and complications","volume":"23","author":"Paroli","year":"2015","journal-title":"Ocular Immunol Inflamm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ajo.2007.01.033","article-title":"Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss","volume":"143","author":"Thorne","year":"2007","journal-title":"Am J Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ophtha.2015.06.041","article-title":"The risk of intraocular pressure elevation in pediatric noninfectious uveitis","volume":"122","author":"Kothari","year":"2015","journal-title":"Ophthalmology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.ophtha.2020.01.036","article-title":"Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids","volume":"127","author":"Thorne","year":"2020","journal-title":"Ophthalmology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semarthrit.2018.11.004","article-title":"Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis","volume":"49","author":"Heiligenhaus","year":"2019","journal-title":"Sem Arthritis Rheum."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients","volume":"69","author":"Calvo-R\u00edo","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, N.69 J)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/09273948.2020.1817501","article-title":"Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis associated uveitis","volume":"29","author":"Maleki","year":"2021","journal-title":"Ocular Immunol Inflamm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3899\/jrheum.171006","article-title":"Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis","volume":"45","author":"Cecchin","year":"2018","journal-title":"J Rheumatol."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.682327\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T05:18:50Z","timestamp":1624857530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.682327\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":27,"alternative-id":["10.3389\/fped.2021.682327"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.682327","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"article-number":"682327"}}